胶质瘤显像剂的研究与应用进展

孙娜; 赵晋华; 乔文礼

doi:10.3760,cma.j.issn.1673-4114.2011.06.003

胶质瘤显像剂的研究与应用进展

上海交通大学附属第一人民医院核医学科, 200080
基金项目:
上海市科委国际科技合作基金(07SP07004)

国家自然科学基金(81171368)

Advances in appUcafion of radiotracers for glioma imaging

Department of Nuclear Medwine, the First People's Hospitd, Shanghai Jiaotong University, Shanghai 200080, China

摘要: 核医学显像在胶质瘤的诊断、分级及预后等方面有重要的临床价值,随着核医学的发展,用于胶质瘤的显像剂也越来越多样化,目前研究应用较多的SPECT显像剂有²⁰¹T1、⁹⁹Tc^m-MIBI、¹²³I-碘代甲基酪氨酸以及新型受体类显像剂¹³¹-I.蝎氯毒素等,PET显像剂主要有葡萄糖代谢显像剂、氨基酸代谢显像剂、胆碱代谢显像剂、核苷酸代谢显像剂、乏氧代谢显像剂等。它们分别提供胶质瘤的物质代谢、细胞增殖、组织乏氧等方面的信息,进而用于临床诊断,该文主要对上述各类显像剂在胶质瘤的应用和进展方面进行论述。
- 神经胶质瘤 /
- 体层摄影术,发射型计算机,单光子 /
- 正电子发射断层显像术 /
- 放射性示踪剂
Abstract: Nuclear medicine imaging plays an important role in diagnosis,grading and prognosis of patients with gliomas.With the development of nuclear medicine,a variety of radiotracers have been pro-posed used as targets for glioma imaging.At present。the most widely used SPECT radiotracers are ²⁰¹T1.⁹⁹Tc^m-MIBI.¹²³I-iodo-methyl tyrosine and ¹³¹I-Buthus martensi Karsch chlorotoxin-like toxin.The most important PET radiotracers include radiolabled glucose,amino acids,choline,nucleotides and hypoxia markers.They can provide the information of substance metabolism,cell proliferation and hypoxia metabolism in gliomas to promote the accurate clinical diagnosis.This review mainly introduces the advances in application of above-mentioned radiotracers in glioma imaging.
- Glioma /
- Tomography,emission-computed,single photon /
- Positron emission tomography /
- Radionctive tracers
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Higa T,Maetani S,Yoichiro K,et al.T1-201 SPECT compared with histopathologic grade in the prognostic assessment of cerebral gliomas.Clin Nucl Med,2001,26(2):119-124.
[2]	Semba T,Sugawara Y,Ochi T,et al.Thallium-201 SPECT in prognostic assessment of malignant gliomas treated with postoperative radiotherapy.Ann Nucl Med,2006,20(4):287-294.
[3]	Cheng X,Li YJ,Xu ZQ,et al.A meta-analysis of ^99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy.J Clin Neurosci,2011,18(3):307-312.
[4]	Henze M,Ozdemir-Sahin N,Hipp P,et al.Comparison of diagnostic accuracy of (18) F-FDG PET,(123) I-IMT-and (99m) Tc-MIBI SPECT:evaluation of tumour progression in irradiated low grade astrocytomas.Nuklearmedizin,2006,45(1):49-56.
[5]	Hellwig D,Kettcr R,Romeike BF,et al.Prospective study of p-[¹²³I] iodo-L-phenylalanine and SPECT for the evaluation of newly diagnosed cerebral lesions:specific confirmation of glioma.Eur J Nucl Med Mol Imaging,2010,37(12):2344-2353.
[6]	乔文礼,赵晋华,邵晓霞,等.¹³¹I-BmK CT的制备及其在胶质瘤荷瘤大鼠体内分布与显像研究.核技术,2011,34(3):213-216.
[7]	Zhao JH,Qiao WL,Zhang Y,et al.Preparation and in vitro evaluation of ¹³¹I-BmK CT as a glioma-targeted agent.Cancer Biother Radiopharm,2010,25(3):353-359.
[8]	Cher LM,Murone C,Lawrentschuk N,et al.Correlation of hypoxic cell fraction and angiogenesis with glucosc metabolic rate in gliomas using ¹⁸F-fluommisonidazole,¹⁸F-FDG PET,and immuno-histochemical studies.J Nucl Med,2006,47(3):410-418.
[9]	Pirotte BJ,Lubansu A,Massager N,et al.Results of pesitmn emis-sion tomography guidance and reassessment of the utility of and indications for stereotactic biopsy in children with infiltrative brainstem tumors.J Neurosurg,2007,107 Suppl5:392-399.
[10]	李伟龙.大鼠C6胶质瘤放射治疗前后¹⁸F-FDG PET/CT显像及病理学变化.放射学实践,2011,26(5):479-482.
[11]	Padma MV,Said S,Jacobs M,et al.Prediction of pathology and survival by FDG PET in gliomas.J Neurooncol,2003,64(3):227-237.
[12]	Spence AM,Muzi M,Mankoff DA,et al.¹⁸F-FDG PET of gliomas at delayed intervals:improved distinction between tumor and normal gray matter.J Nucl Med,2004,45(10):1653-1659.
[13]	Kracht LW,Friese M,Herholz K,et al.Methyl-[¹¹C]-I-methionine uptake as measured by positron emission tomography correlates to micmvessel density in patients with glioma.Eur J Nucl Med Mol Imaging,2003,30(6):868-873.
[14]	邵虹,Trampal C,吴靖川.¹¹C-蛋氨酸PET显像诊断胶质瘤的价值.中华核医学杂志,2003,23(2):75-76.
[15]	胡裕效,朱虹.¹¹C-MET PET显像在脑胶质瘤中的应用进展.放射学实践,2010,25(11):1293-1295.
[16]	理东丽,许乙凯,王全师,等.¹¹C.MET和¹⁸F-FDG PET/CT对胶质瘤诊断的价值比较.核技术,2011,34(2):151-154.
[17]	Weber WA,Wester HJ,Grosu AL,et al.O-(2.[¹⁸F] fluoroethyl)-L-tyrosine and L-[methyl-¹¹C] methionine uptake in brain turnouts:initial results of a comparative study.Eur J Nucl Med,2000,27(5):542-549.
[18]	Popperl G,Kreth FW,Mehrkens JH,et al.FET PET for the evaluation of untreated gliomas:correlation of FET uptake and uptake kinetics with tumor grading.Eur J Nucl Med Mol Imaging,2007,34(12):1933-1942.
[19]	Plotkin M,Blechschmidt C,Auf G,et al.Comparison of F-18 FET PET with F-18 FDG-PET for biopsy planning of non-contrast-enhancing gliomas.Eur Radiol,2010,20(10):2496-2502.
[20]	Floeth FW,Pauleit D,Sabel M,et al.Prognostic value of O-(2-¹⁸F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma.J Nucl Med,2007,48(4):519-527.
[21]	Hutterer M,Nowosielski M,Putzer D,et al.O-(2-¹⁸F-Fluomethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.J Nucl Med,2011,52(6):856-864.
[22]	Mehrkens JH,Pöpperl G,Rachinger W,et al.The positive predic-tive value of O-(2-[¹⁸F] fluoroethyl)-L-tymsine (FET) PET in the diag-nosis of a glioma recurrence after muhimodal treatment.J Neuroon-col,2008,88(1):27-35.
[23]	李方明,聂青,赵文锐,等.CHO PET功能显像:脑胶质瘤诊断和优化放化疗方案.中华神经外科疾病研究杂志,2011,10(2):154-157.
[24]	Hatakeyama T,Kawai N,Nishiyama Y,et al.¹¹C-methionine (MET) and ¹⁸F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma.Eur J Nucl Med Mol Imaging,2008,35(11):2009-2017.
[25]	Tripathi M,Sharma R,D'Souza M,et al.Comparative evaluation of F-18 FDOPA,F-18 FDG,and F-18 FLT PET/CT for metabolic imaging of low grade gliomas.Clin Nucl Med,2009,34(12):878-883.
[26]	Sehiepers C,Dahlbom M,Chen W,et al.Kinetics of 3'-deoxy-3'-¹⁸F-fluorothymidine during treatment monitoring of recurrent high-grade glioma.J Nuel Med,2010,51(5):720-727.
[27]	Rueger MA,Ameli M,Li H,et al.[¹⁸F] FLT PET for non-invasive monitoring of early response to gene therapy in experimental gliomas.Mol Imaging Biol,2011,13(3):547-557.
[28]	Swanson KR,Chakraborty G,Wang CH,et al.Complementary bat distinct roles for MRI and ¹⁸F-fluommisonidazole PET in the assess-ment of human glioblastomas.J Nucl Med,2009,50(1):36-44.

[1]	孙娜 , 赵晋华 , 乔文礼 . 胶质瘤显像剂的研究与应用进展. 国际放射医学核医学杂志, 2011, 35(6): 330-334. doi: 10.3760/cma.j.issn.1673-4114.2011.06.003
[2]	乐亚丽 , 陈跃 . 多种不同PET或PET/CT分子探针在胶质瘤中的应用进展. 国际放射医学核医学杂志, 2013, 37(6): 364-369. doi: 10.3760/cma.j.issn.1673-4114.2013.06.010
[3]	周惠君 , 董萍 , 沈国华 , 李林 . ¹¹C-蛋氨酸PET/CT显像在脑胶质瘤中的应用价值. 国际放射医学核医学杂志, 2015, 39(2): 161-164. doi: 10.3760/cma.j.issn.1673-4114.2015.02.013
[4]	潘越 , 王观筠 , 党浩丹 , 徐白萱 . RGD肽类示踪剂及其PET显像在脑胶质瘤诊疗中的应用. 国际放射医学核医学杂志, 2023, 47(6): 362-366. doi: 10.3760/cma.j.cn121381-202207012-00299
[5]	程林 , 程竞仪 . 氨基酸类正电子显像在胶质瘤中的研究进展. 国际放射医学核医学杂志, 2017, 41(4): 283-287. doi: 10.3760/cma.j.issn.1673-4114.2017.04.009
[6]	杨辉 , 张富强 , 李文亮 , 徐欣 , 李德宇 , 王重韧 , 赵明 . 术中¹²⁵I粒子植入治疗复发性脑胶质瘤的临床研究. 国际放射医学核医学杂志, 2013, 37(6): 345-348. doi: 10.3760/cma.j.issn.1673-4114.2013.06.005
[7]	展凤麟 , 汪世存 , 潘博 , 倪明 , 谢吉奎 , 谢强 , 钱立庭 . ¹¹C-胆碱和¹⁸F-FDG PET/CT显像在脑胶质瘤诊断中的应用. 国际放射医学核医学杂志, 2013, 37(4): 193-195. doi: 10.3760/cma.j.issn.1673-4114.2013.04.001
[8]	张敏 , 何玉林 , 王相成 , 王雪梅 . ¹¹C标记的心脏交感神经受体显像剂的研究进展. 国际放射医学核医学杂志, 2023, 47(2): 105-111. doi: 10.3760/cma.j.cn121381-202208001-00274
[9]	高艳 , 赵晋华 . PET/MRI融合显像在脑胶质瘤诊断和治疗中的研究. 国际放射医学核医学杂志, 2015, 39(1): 71-74, 79.
[10]	高艳 , 赵晋华 . PET/MRI融合显像在脑胶质瘤诊断和治疗中的研究进展. 国际放射医学核医学杂志, 2015, 39(1): 71-74,79. doi: 10.3760/cma.j.issn.1673-4114.2015.01.015

点击查看大图

计量

文章访问数: 1685
HTML全文浏览量: 179
PDF下载量: 2

胶质瘤显像剂的研究与应用进展

Advances in appUcafion of radiotracers for glioma imaging

计量

胶质瘤显像剂的研究与应用进展

English Abstract

Advances in appUcafion of radiotracers for glioma imaging

全文HTML

目录

胶质瘤显像剂的研究与应用进展

Advances in appUcafion of radiotracers for glioma imaging

计量

出版历程

胶质瘤显像剂的研究与应用进展

English Abstract

Advances in appUcafion of radiotracers for glioma imaging

全文HTML

目录